Cancer Medicine · global
Phase 3 benefits of personalized mRNA cancer vaccine revealed: Two-year recurrence-free survival in melanoma improves by 12.2 percentage points
Newly disclosed data quantify the benefits of a Phase 3 trial previously announced only as having met its targets: The vaccine combined with immunotherapy reduced the relative risk of recurrence or death by 42%. However, the full data await formal publication, and whether the treatment extends life remains unresolved.
After melanoma is surgically removed, the next treatment challenge is preventing the cancer from returning. According to Phase 3 trial data disclosed by CancerNetwork, the personalized mRNA cancer vaccine intismeran autogene combined with the immunotherapy pembrolizumab achieved a two-year recurrence-free survival rate of 82.2%, compared with 70.0% in the control group. This difference provides a preliminary, concrete answer to how much benefit adding the vaccine after surgery might offer.
The new information quantifies the benefit. Merck and Moderna announced in August that the INTerpath-001 trial had met its prespecified targets for recurrence-free survival and distant metastasis-free survival, but did not release detailed figures at the time. The latest report indicates that, among 1,137 patients, the combination reduced the relative risk of recurrence or death by 42% compared with pembrolizumab alone; the absolute difference in two-year recurrence-free survival was 12.2 percentage points. These figures describe different aspects of the results: The 42% figure cannot be interpreted as meaning that 42% more patients remained free of recurrence.
The trial enrolled patients with stage IIB to IV cutaneous melanoma whose tumors had been completely removed, evaluating adjuvant treatment after surgery. Recurrence-free survival counts cancer recurrence or death as an event, so the results support the combination's ability to delay these events. They do not establish that patients have been cured, nor can the same effects be directly inferred for other cancers.
The design of intismeran autogene is based on the mutations present in each patient's tumor. Researchers use this information to produce an mRNA therapy that enables the immune system to recognize tumor neoantigens; pembrolizumab blocks the PD-1 immune checkpoint, reducing suppression of the immune response. The rationale for combining them is to provide clues for recognizing cancer cells while helping immune cells continue to function. This is a treatment strategy for existing cancer, rather than a vaccine for preventing cancer in the general population.
The way the data were released also limits the conclusions that can currently be drawn. FirstWord Pharma reported that detailed results leaked ahead of their scheduled presentation at the European Society for Medical Oncology annual meeting. The information currently available is insufficient for a full assessment of confidence intervals, differences in benefit across disease stages, and rates of adverse reactions. The two companies stated in August that no new safety signals had been observed, but this broad statement cannot replace complete safety data.
The most critical unanswered question is whether the reduction in recurrence risk will translate into longer life. Overall survival data remain immature, and the trial requires continued follow-up. The new figures make the potential value of this personalized therapy clearer. Determining its place in treatment after surgery will require the formally published full results, along with an assessment of both its benefits and treatment burden.